A 79-year-old woman, with end stage renal failure (ESRF) due to diabetic nephropathy, presented with generalized involuntary movements for 3 days. She had a history of hypertension, hyperlipidemia, and gouty arthritis. Gabapentin (GBP) 300 mg nocte was prescribed for her postherpetic neuralgia involving her right V 1 dermatome. Ten hours later, she developed generalized involuntary jerky movements, and was also drowsy and unable to walk. She did not take further doses of GBP. On the following 2 days, her involuntary movements persisted but were decreasing in severity. She presented to us on the third day. She had a Glasgow coma scale of 15 and had high frequency multifocal myoclonus involving her neck, bilateral upper extremities, and trunk. Blood tests showed random glucose 8.1 mmol/L, urea 27.4 mmol/L, creatinine 531 mmol/L, adjusted calcium 2.15 mmol/L, phosphate 1.87 mmol/L, and normal liver function test. Computed tomography of the brain reviewed cerebral atrophy. Her medications include calcium supplements, frusemide, amlodipine, isosorbide mononitrate, sodium bicarbonate, and paracetamol. GBP level measured 67 hours later was 23 mmol/L (reference range 70e120 mmol/L). Clonazepam was prescribed but she was unable to tolerate it due to dizziness. On the fifth day, her myoclonus completely subsided. One month later, her renal function remained static and myoclonus did not recur.
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GBP is commonly used to control neuropathic pain and epilepsy. 1, 2 Myoclonus, a sudden, brief, shock-like involuntary movement, can be caused by anoxic brain injury, metabolic derangement, focal brain lesions, medications, and viral infections. 2 Myoclonus is reported in 0.1% to 12.5% of patients using GBP. 2 Myoclonus is classified as focal if only one limb is involved or multifocal if it occurs asynchronously in at least two limbs. High frequency myoclonus refers to twitches at more than one/minute. GBP is cleared by the kidney and its clearance is reduced in the elderly and patients with chronic renal failure (CRF). 3 The half life of GBP is prolonged to >20 hours in patients with CRF as compared to 5 to 8 hours in patient with normal renal function. 3 There have been previous case reports of GBP induced myoclonus in patients with CRF (Table 1 ). 2e5 GBP overdose is the most likely cause of the myoclonus in our patient as she has never had previous myoclonus, there was a clear temporal relationship between myoclonus and GBP, and cessation of myoclonus after GBP was stopped. Uremia alone was unlikely to have been the cause, as her renal function remained static. The dosage of GBP (300 mg) was the lowest among the reported cases. We are unable to obtain GBP level immediately after the onset of mycoclonus. The persistence of mycoclonus even when the drug level fell within the normal range suggested that GBP-induced mycolonus may not be dose related but threshold related. 3 GBP probably lowered the threshold for myoclonus in uremia. 2e5 In general, GBP induced myoclonus is self limited. Low-dose benzodiazepine and renal replacement therapy 5 can be used in case of severe myoclonus.
This case highlights that 300 mg of gabapentin could result in myoclonus in patients with CRF. 
